文献速递胸部肿瘤

度伐利尤单抗三线及以上治疗晚期非小细胞肺癌(ATLANTIC):开放标签单臂2期研究

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
PubMed 文献 · Lancet Oncol · 2018-03-12

ATLANTIC研究是一项2期开放标签单臂试验,纳入444例经治晚期NSCLC患者,按EGFR/ALK状态和PD-L1表达分3个队列,接受度伐利尤单抗10 mg/kg每2周治疗。主要终点为PD-L1高表达患者的客观缓解率,结果显示各队列均有缓解,EGFR-/ALK-患者缓解率高于EGFR+/ALK+患者,安全性与其他抗PD-1/PD-L1药物一致。

要点

  • 度伐利尤单抗在经治晚期NSCLC各队列中均观察到客观缓解。

核心结论

  • 在晚期经治NSCLC中,度伐利尤单抗的临床活性与安全性与其他抗PD-1/PD-L1药物一致。
  • EGFR-/ALK-患者缓解比例高于EGFR+/ALK+患者。
  • EGFR+且PD-L1≥25%患者的临床活性令人鼓舞,值得进一步研究。

研究设计与样本

  • ATLANTIC为2期、开放标签、单臂试验,在亚洲、欧洲和北美139个中心开展。
  • 纳入444例晚期NSCLC患者,既往至少接受过两线系统治疗(含铂化疗,必要时TKI)。
  • 患者分3个队列:队列1为EGFR+/ALK+,队列2和3为EGFR-/ALK-,按PD-L1表达分层。
  • 患者接受度伐利尤单抗10 mg/kg每2周静脉输注,最长12个月。
  • 主要终点为PD-L1表达增加患者中经独立中心审核的客观缓解比例。

主要发现

  • 444例中40例(9%)发生3或4级治疗相关不良事件:队列1为6/111(5%),队列2为22/265(8%),队列3为12/68(18%)。
  • 治疗相关严重不良事件共27/444例(6%),最常见为肺炎(5例[1%])、乏力(3例[1%])和输注相关反应(3例[1%])。

关键数值与推荐

  • 主要终点缓解评估采用RECIST 1.1版,由独立中心审核。
  • PD-L1表达增加定义:队列1和2为≥25%肿瘤细胞表达,队列3为≥90%肿瘤细胞表达。
  • 3或4级治疗相关不良事件最常见包括肺炎(4例[1%])、γ-谷氨酰转移酶升高(4例[1%])、腹泻(3例[1%])和输注相关反应(3例[1%])。

临床怎么用

  • 度伐利尤单抗可作为经治晚期NSCLC的三线及以上治疗选择之一。
  • 治疗前应评估EGFR/ALK状态和PD-L1表达以预估获益。
  • 用药期间需监测肺炎、乏力、输注相关反应等不良事件。

局限性

  • 本研究为单臂设计,无对照组,结论需谨慎解读。
  • 各队列样本量有限,尤其队列3仅68例。
  • 研究不再入组,但仍在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR-/ALK-), but clinical benefit in patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) has not been shown. We assessed the effect of durvalumab (anti-PD-L1) treatment in three cohorts of patients with NSCLC defined by EGFR/ALK status and tumour expression of PD-L1. METHODS: ATLANTIC is a phase 2, open-label, single-arm trial at 139 study centres in Asia, Europe, and North America. Eligible patients had advanced NSCLC with disease progression following at least two previous systemic regimens, including platinum-based chemotherapy (and tyrosine kinase inhibitor therapy if indicated); were aged 18 years or older; had a WHO performance status score of 0 or 1; and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Key exclusion criteria included mixed small-cell lung cancer and NSCLC histology; previous exposure to any anti-PD-1 or anti-PD-L1 antibody; and any previous grade 3 or worse immune-related adverse event while receiving any immunotherapy agent. Patients in cohort 1 had EGFR+/ALK+ NSCLC with at least 25%, or less than 25%, of tumour cells with PD-L1 expression. Patients in cohorts 2 and 3 had EGFR-/ALK- NSCLC; cohort 2 included patients with at least 25%, or less than 25%, of tumour cells with PD-L1 expression, and cohort 3 included patients with at least 90% of tumour cells with PD-L1 expression. Patients received durvalumab (10 mg/kg) every 2 weeks, via intravenous infusion, for up to 12 months. Retreatment was allowed for patients who benefited but then progressed after completing 12 months. The primary endpoint was the proportion of patients with increased tumour expression of PD-L1 (defined as ≥25% of tumour cells in cohorts 1 and 2, and ≥90% of tumour cells in cohort 3) who achieved an objective response, assessed in patients who were evaluable for response per independent central review according to RECIST version 1.1. Safety was assessed in all patients who received at least one dose of durvalumab and for whom any post-dose data were available. The trial is ongoing, but is no longer open to accrual, and is registered with ClinicalTrials.gov, number NCT02087423. FINDINGS: Between Feb 25, 2014, and Dec 28, 2015, 444 patients were enrolled and received durvalumab: 111 in cohort 1, 265 in cohort 2, and 68 in cohort 3. Among patients with at least 25% of tumour cells expressing PD-L1 who were evaluable for objective response per independent central review, an objective response was achieved in 9 (12·2%, 95% CI 5·7-21·8) of 74 patients in cohort 1 and 24 (16·4%, 10·8-23·5) of 146 patients in cohort 2. In cohort 3, 21 (30·9%, 20·2-43·3) of 68 patients achieved an objective response. Grade 3 or 4 treatment-related adverse events occurred in 40 (9%) of 444 patients overall: six (5%) of 111 patients in cohort 1, 22 (8%) of 265 in cohort 2, and 12 (18%) of 68 in cohort 3. The most common treatment-related grade 3 or 4 adverse events were pneumonitis (four patients [1%]), elevated gamma-glutamyltransferase (four [1%]), diarrhoea (three [1%]), infusion-related reaction (three [1%]), elevated aspartate aminotransferase (two [<1%]), elevated transaminases (two [<1%]), vomiting (two [<1%]), and fatigue (two [<1%]). Treatment-related serious adverse events occurred in 27 (6%) of 444 patients overall: five (5%) of 111 patients in cohort 1, 14 (5%) of 265 in cohort 2, and eight (12%) of 68 in cohort 3. The most common serious adverse events overall were pneumonitis (five patients [1%]), fatigue (three [1%]), and infusion-related reaction (three [1%]). Immune-mediated events were manageable with standard treatment guidelines. INTERPRETATION: In patients with advanced and heavily pretreated NSCLC, the clinical activity and safety profile of durvalumab was consistent with that of other anti-PD-1 and anti-PD-L1 agents. Responses were recorded in all cohorts; the proportion of patients with EGFR-/ALK- NSCLC (cohorts 2 and 3) achieving a response was higher than the proportion with EGFR+/ALK+ NSCLC (cohort 1) achieving a response. The clinical activity of durvalumab in patients with EGFR+ NSCLC with ≥25% of tumour cells expressing PD-L1 was encouraging, and further investigation of durvalumab in patients with EGFR+/ALK+ NSCLC is warranted. FUNDING: AstraZeneca.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018. PMID: 29545095. doi:10.1016/S1470-2045(18)30144-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。